Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing often feels like decoding a medical journal, and Viridian Therapeutics鈥� reports are no exception. Clinical trial timelines, antibody engineering details, and cash-runway disclosures can hide across hundreds of pages. If you have ever searched, 鈥淗ow do I find Viridian Therapeutics鈥� quarterly earnings report 10-Q filing?鈥� you already know the challenge.
Stock Titan鈥檚 AI-powered summaries turn those dense sections into plain-English insights. Open a 10-K and our platform immediately flags R&D expense trends, notes on IGF-1R antibody progress, and risk factors unique to thyroid eye disease. Need real-time alerts? We post every Viridian Therapeutics 8-K material events explained within minutes of hitting EDGAR鈥攚hether it is a phase-2 data release or a new licensing deal. For governance watchers, the proxy statement executive compensation breakdown highlights how leadership incentives align with clinical milestones.
Tracking ownership shifts is just as simple. Our dashboard lists Viridian Therapeutics insider trading Form 4 transactions alongside AI context, so you see why an executive bought or sold shares. Prefer live updates? Activate 鈥淰iridian Therapeutics Form 4 insider transactions real-time鈥� alerts before market open. Quarterly comparisons are equally clear: the latest 鈥淰iridian Therapeutics earnings report filing analysis鈥� shows burn-rate changes at a glance, while the 鈥淰iridian Therapeutics annual report 10-K simplified鈥� section connects cash needs to upcoming TED trial costs.
From understanding Viridian Therapeutics SEC documents with AI to locating a single line item on deferred tax assets, every filing type鈥�10-Q, 10-K, 8-K, S-3, or DEF 14A鈥攊s indexed, summarized, and linked. Save hours, spot pivotal disclosures early, and act with confidence.
Viridian Therapeutics, Inc. files an S-3ASR prospectus supplement describing its pipeline and offering mechanics. The company highlights lead programs including veligrotug (an intravenous anti-IGF-1R monoclonal antibody) and VRDN-003 (a planned low-volume, subcutaneous anti-IGF-1R intended for at-home auto-injector use for TED). The filing states VRDN-006 and VRDN-008 are engineered FcRn inhibitors. Stated timelines include VRDN-006 proof-of-concept IgG reduction data in Q3 2025, an anticipated IND submission for VRDN-008 by end of 2025, and anticipated VRDN-003 topline REVEAL-1 and REVEAL-2 data in H1 2026. As of September 3, 2025 the company had 81,668,033 common shares outstanding, 134,864 Series A and 145,160 Series B preferred shares. Use of proceeds is for development, commercialization preparation, working capital and general corporate purposes. The Registration Rights Agreement requires Viridian to use commercially reasonable efforts to register certain shares and explicitly does not include demand or piggyback registration rights.
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian鈥檚 cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei鈥檚 development success and Viridian鈥檚 ongoing manufacturing obligations.
FAQ
What is the current stock price of Viridian Therapeutics (VRDN)?
What is the market cap of Viridian Therapeutics (VRDN)?
